AN OPEN-LABEL SAFETY PROGRAM FOR THE USE OF ZALCITABINE (DIDEOXYCYTIDINE; DDC) IN PEDIATRIC PATIENTS WITH SYMPTOMATIC HIV INFECTION WHO HAVE FAILED OR ARE INTOLERANT TO AZT MONOTHERAPY, OR WHO HAVE COMPLETED OTHER DDC PROTOCOLS, OR ARE INELIGIBLE FOR OTHER ONGOING CLINICAL STUDIES: